PCI-32765 racemate

CAS No. 936563-87-0

PCI-32765 racemate( Ibrutinib Racemate | PCI32765 Racemate | PCI 32765 Racemate )

Catalog No. M16704 CAS No. 936563-87-0

A potent a+M7692nd highly selective Btk inhibitor with IC50 of 0.5 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
50MG 235 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    PCI-32765 racemate
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent a+M7692nd highly selective Btk inhibitor with IC50 of 0.5 nM.
  • Description
    A potent a+M7692nd highly selective Btk inhibitor with IC50 of 0.5 nM; modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.Blood Cancer Approved.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Ibrutinib Racemate | PCI32765 Racemate | PCI 32765 Racemate
  • Pathway
    Tyrosine Kinase
  • Target
    BTK
  • Recptor
    BTK
  • Research Area
    Cancer
  • Indication
    Blood cancer

Chemical Information

  • CAS Number
    936563-87-0
  • Formula Weight
    440.4971
  • Molecular Formula
    C25H24N6O2
  • Purity
    >98% (HPLC)
  • Solubility
    10 mM in DMSO
  • SMILES
    C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N
  • Chemical Name
    2-Propen-1-one, 1-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Honigberg LA, et al. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80. 2. Herman SE, et al. Blood. 2014 May 22;123(21):3286-95. 3. Kohrt HE, et al. Blood. 2014 Mar 20;123(12):1957-60.
molnova catalog
related products
  • PCI-32765 racemate

    A potent a+M7692nd highly selective Btk inhibitor with IC50 of 0.5 nM.

  • BLK degrader 1

    BLK degrader 1 is a selective B lymphoid tyrosine kinase (BLK) degrader with anticancer activity and can be used for cancer research.

  • Acalabrutinib

    A novel, irreversible, covalent second-generation BTK inhibitor with IC50 of 3 nM.